Global Blood Therapeutics, Inc.: New Data Supporting the Potential Use of Oxbryta (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase
United States Steven Immergut Courtney Roberts Clark Brown Centers For Disease Blood Disorders Center
Source: finanznachrichten.de